摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-叔丁基 2-(叔丁氧基羰基氨基)-4-疏基丁酸酯 | 630108-94-0

中文名称
(S)-叔丁基 2-(叔丁氧基羰基氨基)-4-疏基丁酸酯
中文别名
(S)-叔丁基2-(叔丁氧基羰基氨基)-4-疏基丁酸酯
英文名称
N-tert-butoxycarbonyl-1-homocysteine tert-butyl ester
英文别名
N-tert-butoxycarbonyl-L-homocysteine tert-butyl ester;N-tert-butoxycarbonyl-L-homocystine tert-butyl ester;tert-butyl N-(tert-butoxycarbonyl)-L-homocysteinate;tert-butyl (tert-butoxycarbonyl)-L-homocysteinate;tert-butyl N-(tert-butoxycarbonyl)homocysteinate;Nα-Boc-L-homocysteine t-butyl ester;(S)-Tert-butyl 2-(tert-butoxycarbonylamino)-4-mercaptobutanoate;tert-butyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-sulfanylbutanoate
(S)-叔丁基 2-(叔丁氧基羰基氨基)-4-疏基丁酸酯化学式
CAS
630108-94-0
化学式
C13H25NO4S
mdl
——
分子量
291.412
InChiKey
AFSKWXGSKKCBDW-VIFPVBQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    391.8±37.0 °C(Predicted)
  • 密度:
    1.065±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    19
  • 可旋转键数:
    8
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.85
  • 拓扑面积:
    65.6
  • 氢给体数:
    2
  • 氢受体数:
    5

SDS

SDS:38e76722be61ed23953b5784108029e8
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Radiosynthesis and Biological Evaluation of l- and d-S-(3-[18F]Fluoropropyl)homocysteine for Tumor Imaging Using Positron Emission Tomography
    摘要:
    Interest in radiolabeled amino acids for metabolic imaging of cancer and limitations with [C-11]methionine has prompted the development of a new F-18-labeled methionine derivative S-(3-[F-18]fluoropropyl)homocysteine ([F-18]FPHCys). The L and D enantiomers of [F-18]FPHCys were prepared from their respective protected S-(3-tosyloxypropyl)homocysteine precursors 1 by [F-18]fluoride substitution using K-2.2.2 and potassium oxalate, followed by acid hydrolysis on a Tracerlab FXFN synthesis module. [F-18]-L-FPHCys and [F-18]-D-FPHCys were isolated in 20 +/- 5% radiochemical yield and >98% radiochemical and enantiomeric purity in 65 mm. Competitive Take studies in A375 and HT29 tumor cells suggest that L- and n-[F-18]FPHCys are taken up by the L-transporter system. [F-18]-L-FPHCys and [F-18]-D-FPHCys displayed good stability In Vivo without incorporation into protein at least 2 h postinjection. Biodistribution studies demonstrate good uptake in A375 tumor-bearing rodents with tumor to blood ratios of 3.5 and 5.0 for [F-18]-L-FPHCys and [F-18]-D-FPHCys, respectively, at 2 h postinjection.
    DOI:
    10.1021/jm101513q
  • 作为产物:
    参考文献:
    名称:
    具有连接到核糖的C2的高半胱氨酸单元的S-核糖基同型半胱氨酸类似物的异构体类似物的合成。
    摘要:
    LuxS(S-核糖基同型半胱氨酸酶; EC 4.4.1.21)是一种催化硫醚键在S-核糖基同型半胱氨酸(SRH)催化途径中裂解的酶,产生高半胱氨酸和4,5-二羟基-2,3-戊二酮(DPD) )。DPD是称为自动诱导剂2(AI-2)的信号分子的前体,负责负责确定为细胞与细胞之间的通讯的细菌群体感应(QS)。LuxS抑制剂应能够干扰其催化途径,从而防止自诱导分子的形成。在这项工作中,通过将相应的2-溴-2-脱氧五呋喃呋喃糖基糖与高半胱氨酸阴离子偶联来尝试合成2-脱氧-2-溴-SRH类似物。
    DOI:
    10.1016/j.bmcl.2017.03.004
  • 作为试剂:
    参考文献:
    名称:
    Revisiting synthetic preparation of the quorum sensing substrate S-d-ribosyl-l-homocysteine (SRH)
    摘要:
    Cleavage of the thioether bond of S-D-ribosyl-L-homocysteine (SRH) by the enzyme S-ribosylhomocysteinase (LuxS) serves as the final biosynthetic step in the generation of the quorum sensing autoinducer AI-2 by bacteria. Herein, a revised chemical synthesis of SRH is presented at convenient scale and purity for in vitro studies of LuxS. Potassium bis(trimethylsilyl) amide (KHMDS) is identified as a judicious base for the formation of the thioether of the target compound from readily-accessible precursors: a thiol nucleophile derived from L-homocystine and a sulfonate-activated D-ribosyl electrophile. The exclusive use of acid-labile protecting groups allows for facile deprotection to the final product, producing the TFA salt of SRH in five synthetic steps and 26% overall yield. The chemically-synthesized material is isolated at high purity and demonstrated to serve as the LuxS substrate by an in vitro assay. (C) 2014 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.carres.2014.05.009
点击查看最新优质反应信息

文献信息

  • Nitric oxide synthase inhibitors
    申请人:——
    公开号:US20020010366A1
    公开(公告)日:2002-01-24
    The present invention relates to novel amidino compound of formula (I). 1 to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use as selective inhibitors of inducible nitric oxide synthase.
    本发明涉及一种新的式(I)的酰胺化合物,其制备方法,含有它们的药物组合物,以及它们在治疗中的应用,特别是作为诱导型一氧化氮合酶的选择性抑制剂的用途。
  • Design and Synthesis of Substrate and Intermediate Analogue Inhibitors of <i>S</i>-Ribosylhomocysteinase
    作者:Gang Shen、Rakhi Rajan、Jinge Zhu、Charles E. Bell、Dehua Pei
    DOI:10.1021/jm060047g
    日期:2006.5.1
    indicate that the compounds act as reversible, competitive inhibitors against LuxS, with the most potent inhibitors having K(I) values in the submicromolar range. These represent the most potent LuxS inhibitors that have been reported to date. Cocrystal structures of LuxS bound with two of the inhibitors largely confirmed the design principles, i.e., the importance of both the homocysteine and ribose moieties
    S-核糖基同型半胱氨酸酶(LuxS)催化S-核糖基同型半胱氨酸(SRH)中硫醚键的裂解,产生高半胱氨酸和4,5-二羟基-2,3-戊二酮,自动诱导剂2的前体。交流,并可能提供一类新型的抗菌剂。LuxS在催化过程中利用二价金属离子作为路易斯酸。在这项工作中,设计和合成了底物SRH和2-酮中间体的一系列结构类似物。动力学研究表明,该化合物可作为可逆的,竞争性的LuxS抑制剂,而最有效的抑制剂的K(I)值在亚微摩尔范围内。这些代表了迄今为止已报道的最有效的LuxS抑制剂。
  • Inhibition of inducible nitric oxide synthase by acetamidine derivatives of hetero-substituted lysine and homolysine
    作者:Robert J Young、Richard M Beams、Keith Carter、Helen A.R Clark、Diane M Coe、C.Lynn Chambers、P.Ifeyinwa Davies、John Dawson、Martin J Drysdale、Karl W Franzman、Colin French、Simon T Hodgson、Harold F Hodson、Savvas Kleanthous、Peter Rider、Daniela Sanders、David A Sawyer、Keith J Scott、Barry G Shearer、Richard Stocker、Steven Smith、Miriam C Tackley、Richard G Knowles
    DOI:10.1016/s0960-894x(00)00055-x
    日期:2000.3
    The synthesis and in vitro evaluation of the acetamidine derivatives of hetero-substituted lysine and homolysine analogues have identified potent inhibitors of human nitric oxide synthase enzymes, including examples with marked selectivity for the inducible isoform.
    杂取代赖氨酸和高赖氨酸类似物的乙am衍生物的合成和体外评估已鉴定出人一氧化氮合酶的有效抑制剂,包括对诱导型亚型具有明显选择性的实例。
  • Catalytic Mechanism of <i>S</i>-Ribosylhomocysteinase (LuxS):  Direct Observation of Ketone Intermediates by <sup>13</sup>C NMR Spectroscopy
    作者:Jinge Zhu、Xubo Hu、Eric Dizin、Dehua Pei
    DOI:10.1021/ja0369663
    日期:2003.11.1
    and kinetic competence was demonstrated. The results support a catalytic mechanism in which the metal ion catalyzes an internal redox reaction, shifting the carbonyl group from the C-1 position to the C-3 position. Subsequent beta-elimination at the C-4 and C-5 positions releases homocysteine as a free thiol. The results also suggest that Cys-84 and Glu-57 are the possible general acids/bases for proton
    S-核糖同型半胱氨酸酶 (LuxS) 催化 S-核糖同型半胱氨酸 (SRH) 的硫醚键断裂,产生 l-同型半胱氨酸和 4,5-二羟基-2,3-戊二酮 (DHPD)。这是革兰氏阳性菌和革兰氏阴性菌中 II 型自诱导剂 (AI-2) 生物合成途径的关键步骤。先前的研究表明,LuxS 含有催化必需的 Fe2+ 离子。使用 2-和 3-13C-标记的 SRH 作为底物和 13C NMR 光谱研究了 LuxS 的催化机制。这些研究揭示了催化途径中存在 2- 和 3- 酮中间体。化学合成了 2-酮中间体,并证明了其化学和动力学能力。结果支持金属离子催化内部氧化还原反应的催化机制,将羰基从 C-1 位置移动到 C-3 位置。随后在 C-4 和 C-5 位置进行 β-消除将高半胱氨酸作为游离硫醇释放。结果还表明,Cys-84 和 Glu-57 是催化过程中质子转移的可能的通用酸/碱,并且酮中间体在重新结合和反应完成之前从酶活性位点释放。
  • New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms
    作者:Sophie S. Spurr、Elliott D. Bayle、Wenyu Yu、Fengling Li、Wolfram Tempel、Masoud Vedadi、Matthieu Schapira、Paul V. Fish
    DOI:10.1016/j.bmcl.2016.07.041
    日期:2016.9
    where the polar 5-nitrile group was shown by crystallography to bind in the hydrophobic pocket of DOT1L. In addition, we show that a polar nitrile group can be used as a non-traditional replacement for heavy halogen atoms.
    公开了许多新的核苷衍生物作为DOT1L活性的抑制剂。SARs证实,可以通过在5位(5、6、12)掺入极性基团和小的杂环或通过使用其他含氮碱基(18)来实现DOT1L抑制。根据这些结果,CN-SAH(19)被确定为DOT1L活性的有效和选择性抑制剂,其中结晶晶体显示极性5腈基结合在DOT1L的疏水口袋中。此外,我们表明极性腈基可以用作重卤素原子的非传统替代物。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物